Meeting
2012 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors.
Authors
David S. Mendelson
Pinnacle Oncology Hematology, Scottsdale, AZ
David S. Mendelson , Lee S. Rosen , Francisco Robert , E. Gabriela Chiorean , Jonathan Wade Goldman , Ben K. Seon , Delia Alvarez , Bonne J. Adams , Charles P. Theuer , Bryan R. Leigh , Michael S. Gordon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Angiogenesis
Clinical Trial Registration Number
NCT01332721
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3034)
DOI
10.1200/jco.2012.30.15_suppl.3034
Abstract #
3034
Poster Bd #
11H
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
First Author: Lee S. Rosen
Poster
2018 ASCO Annual Meeting
A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.
First Author: Dongmei Ji
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward
Poster
2017 ASCO Annual Meeting
A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.
First Author: Nai-Jung Chiang